Matches in SemOpenAlex for { <https://semopenalex.org/work/W2519753935> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2519753935 abstract "The overview: In recent years, the South Korean economy has evolved from light goods, to heavy industry, to high tech and biotech. Along the way, the country has built a thoroughly modern legal and regulatory framework, an arguably world class educational infrastructure, and an unusually productive level of public-private partnership activity. How did it get here?: Migrating from a heavy manufacturing economy in the aftermath of the Korean War, South Korea began turning its attention to biopharmaceuticals as an opportunity to leverage the country’s increasing R&D and innovation capabilities, while relieving pressure to meet the healthcare needs and demands of an increasingly mature population. In 1994, the government launched the first national initiative to grow the industry-the “Biotech 2000” plan, investing roughly $20 billion for various biotech-related research initiatives from 1994 to 2000. This was followed by a second government-supported plan dubbed “Bio-Vision 2016,” a ten-year initiative with the goal of making South Korea one of the leading hubs of the biotech industry by 2016. The past decade has witnessed the formation of several key collaborations between South Korean companies and multi-national biopharma firms. Pfizer, AstraZeneca, Bristol-Myers Squibb, Sanofi, Novartis, and Otsuka have all invested heavily in local research and development. What’s the outcome?: As of 2012, South Korea’s top 20 biopharma companies (ranked by 2012 revenue) now total $6,978,110,000. According to the Bloomberg Global Innovation Index, South Korea ranks #1 in the world as the most innovative country in 2015 when considering a variety of metrics such as R&D capacity, productivity, and patent activity. The country’s annual R&D spending totals more than 4 percent of GDP (Source: The World Bank). To support the company’s rapid growth, Samsung announced plans in 2015 to build two more biologics manufacturing plants, at a cost of roughly $1.5 billion, to make the nation one of the largest biologics manufacturers worldwide. Samsung Bioepis is also planning a US IPO in 2016. According to a 2014 IMS report, South Korea’s biopharmaceutical industry is currently ranked fifteenth in the world, and is categorized alongside the United States, the EU5 nations, Japan, and Canada. From these actions, South Korea now ranks among the leading nations on other development indicators such as healthcare, education and R&D expenditure. South Korean life expectancy is now higher than the OECD average at 81 years old." @default.
- W2519753935 created "2016-09-23" @default.
- W2519753935 creator A5001434498 @default.
- W2519753935 creator A5026444271 @default.
- W2519753935 creator A5061671830 @default.
- W2519753935 creator A5086861101 @default.
- W2519753935 date "2016-01-01" @default.
- W2519753935 modified "2023-09-28" @default.
- W2519753935 title "The Modern Merits of South Koreas Biopharmaceutical Industry" @default.
- W2519753935 hasPublicationYear "2016" @default.
- W2519753935 type Work @default.
- W2519753935 sameAs 2519753935 @default.
- W2519753935 citedByCount "0" @default.
- W2519753935 crossrefType "journal-article" @default.
- W2519753935 hasAuthorship W2519753935A5001434498 @default.
- W2519753935 hasAuthorship W2519753935A5026444271 @default.
- W2519753935 hasAuthorship W2519753935A5061671830 @default.
- W2519753935 hasAuthorship W2519753935A5086861101 @default.
- W2519753935 hasConcept C10138342 @default.
- W2519753935 hasConcept C119857082 @default.
- W2519753935 hasConcept C138885662 @default.
- W2519753935 hasConcept C144024400 @default.
- W2519753935 hasConcept C144133560 @default.
- W2519753935 hasConcept C149923435 @default.
- W2519753935 hasConcept C153083717 @default.
- W2519753935 hasConcept C162324750 @default.
- W2519753935 hasConcept C195487862 @default.
- W2519753935 hasConcept C2778137410 @default.
- W2519753935 hasConcept C2908647359 @default.
- W2519753935 hasConcept C41008148 @default.
- W2519753935 hasConcept C41895202 @default.
- W2519753935 hasConcept C50522688 @default.
- W2519753935 hasConcept C71750763 @default.
- W2519753935 hasConceptScore W2519753935C10138342 @default.
- W2519753935 hasConceptScore W2519753935C119857082 @default.
- W2519753935 hasConceptScore W2519753935C138885662 @default.
- W2519753935 hasConceptScore W2519753935C144024400 @default.
- W2519753935 hasConceptScore W2519753935C144133560 @default.
- W2519753935 hasConceptScore W2519753935C149923435 @default.
- W2519753935 hasConceptScore W2519753935C153083717 @default.
- W2519753935 hasConceptScore W2519753935C162324750 @default.
- W2519753935 hasConceptScore W2519753935C195487862 @default.
- W2519753935 hasConceptScore W2519753935C2778137410 @default.
- W2519753935 hasConceptScore W2519753935C2908647359 @default.
- W2519753935 hasConceptScore W2519753935C41008148 @default.
- W2519753935 hasConceptScore W2519753935C41895202 @default.
- W2519753935 hasConceptScore W2519753935C50522688 @default.
- W2519753935 hasConceptScore W2519753935C71750763 @default.
- W2519753935 hasIssue "2" @default.
- W2519753935 hasLocation W25197539351 @default.
- W2519753935 hasOpenAccess W2519753935 @default.
- W2519753935 hasPrimaryLocation W25197539351 @default.
- W2519753935 hasRelatedWork W1499665004 @default.
- W2519753935 hasRelatedWork W1545373192 @default.
- W2519753935 hasRelatedWork W1585921504 @default.
- W2519753935 hasRelatedWork W2037006012 @default.
- W2519753935 hasRelatedWork W2072584782 @default.
- W2519753935 hasRelatedWork W224256463 @default.
- W2519753935 hasRelatedWork W2314400620 @default.
- W2519753935 hasRelatedWork W2316409991 @default.
- W2519753935 hasRelatedWork W2335453175 @default.
- W2519753935 hasRelatedWork W2523210713 @default.
- W2519753935 hasRelatedWork W2616682005 @default.
- W2519753935 hasRelatedWork W2994575807 @default.
- W2519753935 hasRelatedWork W3015746230 @default.
- W2519753935 hasRelatedWork W3098463433 @default.
- W2519753935 hasRelatedWork W3160268367 @default.
- W2519753935 hasRelatedWork W316092279 @default.
- W2519753935 hasRelatedWork W3180110617 @default.
- W2519753935 hasRelatedWork W349249908 @default.
- W2519753935 hasRelatedWork W2184846164 @default.
- W2519753935 hasRelatedWork W2734882244 @default.
- W2519753935 hasVolume "8" @default.
- W2519753935 isParatext "false" @default.
- W2519753935 isRetracted "false" @default.
- W2519753935 magId "2519753935" @default.
- W2519753935 workType "article" @default.